Clinical trials: Cancer, Advanced
Gastric Cancer
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving higher doses may kill more tumor cells.
- Trial name
- NCT00002722
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Volunteers
- 135 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03698994
- Testing
- Pharmacokinetic Study, Ulixertinib
- Where
- 107 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body.
- Trial name
- NCT00942877
- Testing
- AZD2171
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer.
- Trial name
- NCT00678769
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Progression, Survival
PD-L1 Expression in Advanced Osteosarcoma
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment.
- Trial name
- NCT03582527
- Testing
- all study participants
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Advanced Lung Cancer, Lung Metastasis
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
BMD006 is an off-the-shelf antitumor mRNA vaccine targeting lung cancer and lung metastatic solid tumors. This is a single-center, open-label, dose-escalation clinical trial.
- Trial name
- NCT06928922
- Testing
- BMD006 monotherapy, BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation), BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors)…
- Trial name
- NCT04770246
- Testing
- TAS-117
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 17 people
- Sponsor
- Taiho Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer.
- Trial name
- NCT00256841
- Testing
- Chemotherapy, Radiation Therapy
- Where
- United States
- Sponsor
- Clinical Oncology Research Associates
Kidney Cancer
PS-341 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney…
- Trial name
- NCT00017329
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Lung Carcinoma, Stage III Lung Cancer AJCC v8
BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers
This clinical trial aims to develop a new care delivery model, called BeWell360-Care Giver (CG), to support caregivers of patients living with lung cancer that may have spread from where it first started to nearby tissue, lymph…
- Conditions
- Advanced Lung Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05640765
- Testing
- Best Practice, Educational Intervention, Health Promotion and Education
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ovarian Cancer
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System
Primary Objective: To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system.
- Trial name
- NCT00837993
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer Patients Candidate for Radical Cystectomy
Preoperative Subclinical DVT Screening in Locally Advanced Bladder Cancer Patients Candidate for Radical Cystectomy.
Preoperative subclinical DVT screening in locally advanced bladder cancer patients candidate for radical cystectomy.
- Trial name
- NCT04502498
- Testing
- Lower limb duplex & doppler
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach.
- Trial name
- NCT00629798
- Testing
- Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Human Cancers
Phase I Study of MOv18 IgE
This first in human study of the new therapeutic antibody MOv18 immunoglobulin (Ig) E, which targets a protein called folate receptor alpha (FRa), in patients with advanced cancer seeks to demonstrate the potential for the use of…
- Trial name
- NCT02546921
- Testing
- MOv18 IgE
- Where
- 4 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- Cancer Research UK
Gastric Cancer
Surgery for Obstructed Gastric Carcinoma
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to…
- Trial name
- NCT07435025
- Testing
- palliative gastric resection, palliative bypass
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Zagazig University
Prostate Cancer, Osteoporosis
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation
Osteoporosis, or thinning of the bones is a common disorder which can cause significant morbidity in terms of pain and fracture. One of the causes of osteoporosis is a low or absent testosterone level.
- Trial name
- NCT00124410
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- AHS Cancer Control Alberta
Metastatic Solid Tumors
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
- Trial name
- NTRK (NCT04010240)
- Testing
- No intervention (this is a retrospective cohort study)
- Where
- France
- Volunteers
- 3,820 people
- Sponsor
- Institut Bergonié
Residual Tumor, Disease-free Survival
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
To assess the feasibility, Residual Tumor, complication rate and survival of totally laparoscopic primary cytoreduction in carefully selected patients with Advanced Ovarian Cancer, compared with abdominal primary cytoreduction in…
- Conditions
- Residual Tumor, Disease-free Survival, Overall Survival
- Trial name
- NCT02980185
- Testing
- Laparoscopic primary cytoreduction
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Università degli Studi dell'Insubria
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.